MA49357A - Composés, compositions et méthodes permettant de moduler le cftr - Google Patents

Composés, compositions et méthodes permettant de moduler le cftr

Info

Publication number
MA49357A
MA49357A MA049357A MA49357A MA49357A MA 49357 A MA49357 A MA 49357A MA 049357 A MA049357 A MA 049357A MA 49357 A MA49357 A MA 49357A MA 49357 A MA49357 A MA 49357A
Authority
MA
Morocco
Prior art keywords
compositions
compounds
methods
modulating cftr
cftr
Prior art date
Application number
MA049357A
Other languages
English (en)
Inventor
Cecilia M Bastos
David Kombo
Benito Munoz
Daniel Parks
Original Assignee
Proteostasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteostasis Therapeutics Inc filed Critical Proteostasis Therapeutics Inc
Publication of MA49357A publication Critical patent/MA49357A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
MA049357A 2015-10-06 2016-10-06 Composés, compositions et méthodes permettant de moduler le cftr MA49357A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237887P 2015-10-06 2015-10-06
US201662277600P 2016-01-12 2016-01-12
US201662319433P 2016-04-07 2016-04-07

Publications (1)

Publication Number Publication Date
MA49357A true MA49357A (fr) 2020-04-22

Family

ID=57145069

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049357A MA49357A (fr) 2015-10-06 2016-10-06 Composés, compositions et méthodes permettant de moduler le cftr

Country Status (16)

Country Link
US (3) US10550106B2 (fr)
EP (1) EP3359536B1 (fr)
JP (1) JP6929276B2 (fr)
KR (2) KR20250136942A (fr)
CN (1) CN108430994B (fr)
AU (2) AU2016336437B2 (fr)
BR (1) BR112018007021B1 (fr)
CA (1) CA3000483C (fr)
IL (1) IL258486B (fr)
MA (1) MA49357A (fr)
MX (1) MX382725B (fr)
NZ (1) NZ741093A (fr)
RU (1) RU2752567C2 (fr)
SA (1) SA518391268B1 (fr)
SG (1) SG11201802798WA (fr)
WO (1) WO2017062581A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157917B1 (fr) * 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Composés, compositions et procédés pour augmenter l'activité du cftr
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
WO2017062581A1 (fr) * 2015-10-06 2017-04-13 Proteostasis Therapeutics, Inc. Composés, compositions et méthodes permettant de moduler le cftr
AU2016379388A1 (en) * 2015-12-22 2018-07-12 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
US10662207B2 (en) 2016-04-07 2020-05-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
WO2017196843A1 (fr) 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Procédés d'identification de modulateurs du cftr
US10899751B2 (en) 2016-06-21 2021-01-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US20200055844A1 (en) * 2017-04-28 2020-02-20 Proteostasis Therapeutics, Inc. 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
AU2018346602B2 (en) 2017-10-06 2024-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods for increasing CFTR activity
CN107778282B (zh) * 2017-11-03 2020-04-10 中山大学 喹啉-吲哚衍生物及其在制备治疗阿尔茨海默病的药品中的应用
EP3814336A1 (fr) 2018-06-27 2021-05-05 Proteostasis Therapeutics, Inc. Composés améliorant l'activité du protéasome
CN109663129B (zh) * 2019-02-27 2021-05-11 四川大学华西第二医院 扩张型心肌病治疗药物及其应用
WO2021086957A1 (fr) * 2019-11-01 2021-05-06 Fmc Corporation Nouveau procédé efficace de synthèse de 2-amino-5-chloro-n-,3-diméthylbenzamide
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300405A (en) 2020-08-20 2023-04-01 Univ Leland Stanford Junior Methods for treating respiratory diseases characterized by excessive secretion of mucus
CN112279773B (zh) * 2020-10-29 2022-01-07 山东兴强化工产业技术研究院有限公司 一种高品质间苯二胺的合成方法
CN112142615B (zh) * 2020-10-29 2021-11-23 山东兴强化工产业技术研究院有限公司 一种异邻苯二甲酰亚胺的制备方法
CN112300009A (zh) * 2020-10-29 2021-02-02 山东兴强化工产业技术研究院有限公司 一种间苯二胺的制备方法
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3249378A1 (fr) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
IL314691A (en) 2022-02-03 2024-10-01 Vertex Pharma PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
CN118974059A (zh) 2022-02-08 2024-11-15 弗特克斯药品有限公司 囊性纤维化跨膜传导调控因子的调节剂
CN114436864A (zh) * 2022-02-17 2022-05-06 浙江鼎龙科技股份有限公司 一种2-甲基-5氨基苯酚的制备方法
CA3253026A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
WO2025233174A1 (fr) 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Dérivés de benzimidazole utilisés en tant qu'inhibiteurs de cgas

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870712A (en) * 1972-03-17 1975-03-11 Lilly Co Eli Cinchoninic acid derivatives
DE3812225A1 (de) 1988-04-13 1989-10-26 Basf Ag Isoxazol(isothiazol)-5-carbonsaeureamide
US5523408A (en) * 1994-03-25 1996-06-04 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
RO114445B1 (ro) * 1994-05-27 1999-04-30 Smithkline Beecham S.P.A. Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament
BR9606546A (pt) 1995-08-02 1998-07-14 Uriach & Cia Sa J Novas carboxamidas com atividade fungicida
DE69628705T2 (de) 1995-08-24 2004-05-13 Basf Ag Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
WO1998057931A2 (fr) 1997-06-19 1998-12-23 Sepracor Inc. Agents antimicrobiens quinoleine-indole, utilisations et compositions associees
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
EP0957099B1 (fr) 1998-04-15 2002-11-20 Pfizer Products Inc. Carboxamides hétérocycliques
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US6864265B2 (en) * 2000-09-15 2005-03-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
CA2484209C (fr) 2002-05-03 2013-06-11 Exelixis, Inc. Modulateurs de proteine kinase et procedes d'utilisation
ZA200603515B (en) 2003-10-08 2007-11-28 Vertex Pharma Modulators of ATP-binding cassette transporters
RU2006120549A (ru) 2003-11-14 2007-12-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты
WO2005077345A1 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Composes pour le traitement de la maladie du reflux gastro-oesophagien
WO2005077373A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique ii
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
SE0401969D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
WO2006031806A2 (fr) 2004-09-10 2006-03-23 Atherogenics, Inc. 2-thiopyrimidinones utilises en tant qu'agents therapeutiques
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
DE602006018301D1 (de) 2005-06-22 2010-12-30 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
WO2007075896A2 (fr) 2005-12-22 2007-07-05 Kemia, Inc. Inhibiteurs de cytokine heterocycliques
KR101394245B1 (ko) 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
WO2007086584A1 (fr) 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. NOUVEL INHIBITEUR DE FabK ET DE FabI/K
TW200815351A (en) 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
WO2008046072A2 (fr) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Inducteurs chimiques de la neurogénèse
US8193225B2 (en) 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
CN101528744A (zh) 2006-10-20 2009-09-09 Irm责任有限公司 用于调节c-kit和pdgfr受体的组合物和方法
WO2008070739A1 (fr) 2006-12-06 2008-06-12 Cytokinetics, Inc. Activateurs de ksp
WO2009005269A2 (fr) 2007-06-29 2009-01-08 Sk Holdings Co., Ltd. Composition pharmaceutique contenant des dérivés d'isoxazole destinée à prévenir et à traiter la resténose
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
CN101796036A (zh) 2007-08-02 2010-08-04 欧加农股份有限公司 作为trpv1调节剂的5-苯基异噁唑-3-甲酰胺衍生物
WO2009076593A1 (fr) * 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulateurs de régulateur de conductance transmembranaire de fibrose cystique
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090318429A1 (en) 2008-04-28 2009-12-24 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
AU2010211114A1 (en) 2009-02-04 2011-06-30 Msd Oss B.V. Isoxazole-5-carboxamide derivatives
KR101748891B1 (ko) 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
IN2012DN00352A (fr) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011008931A2 (fr) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Composés arylpyrimidines et thérapie de combinaison comprenant ceux-ci pour traiter une mucoviscidose et des troubles apparentés
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
BR112013000925A2 (pt) 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh compostos heterocíclicos como pesticidas
DK2684880T3 (en) 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
CA2736441A1 (fr) 2011-04-06 2012-10-06 The Regents Of The University Of California Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique
EP2736883B1 (fr) 2011-07-29 2019-09-04 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
FR2980212A1 (fr) 2011-09-16 2013-03-22 Agronomique Inst Nat Rech Augmentation de la recombinaison meiotique chez les plantes par inhibition de la proteine fancm
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038386A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Composés hétérocycliques destinés au traitement de la mucosviscidose
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
BR102013003576B8 (pt) 2012-02-16 2022-10-11 Dow Agrosciences Llc Método para produzir n-ciano-s-metil-s-[1-(6-tri-flúormetil-3-piridinil)etil]sulfilimina
UA110436C2 (en) 2012-03-06 2015-12-25 Zoetis Llc Antibacterial phenol compounds
WO2013146970A1 (fr) 2012-03-29 2013-10-03 第一三共株式会社 Nouveau dérivé de quinoléine
WO2014144860A1 (fr) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Correcteurs agissant par l'intermédiaire de msd1 de la protéine cftr
WO2014181287A1 (fr) 2013-05-09 2014-11-13 Piramal Enterprises Limited Composés hétérocyclyliques et leurs utilisations
MX2015017532A (es) 2013-06-26 2016-10-26 Proteostasis Therapeutics Inc Métodos para modular la actividad del regulador de transmembrana de fibrosis quística.
US9920073B2 (en) 2013-10-04 2018-03-20 Drexel University Compositions useful for inhibiting HIV-1 infection and methods using same
CA2942387A1 (fr) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Composes, compositions et procedes pour augmenter l'activite cftr
AU2015229188A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
WO2015154169A1 (fr) 2014-04-09 2015-10-15 The University Of British Columbia Composés de site de (bf3) ayant une fonction 3 de liaison utilisés en tant qu'agents thérapeutiques et leurs procédés d'utilisation
EP3157917B1 (fr) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Composés, compositions et procédés pour augmenter l'activité du cftr
US9855249B2 (en) 2014-10-02 2018-01-02 Flatley Discovery Lab, Llc Isoxazole compounds and methods for the treatment of cystic fibrosis
WO2016105484A1 (fr) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Dérivés d'amide 5-(hétéro)arylpyrazol-3-carboxylique ou d'amide 1-(hétéro)aryltriazol-4-carboxylique utiles pour le traitement, entre autres, de la fibrose kystique
WO2016105468A1 (fr) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Dérivés de 3-hétéroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
CA2971850A1 (fr) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derives d'amides 5-phenyl- ou 5-heteroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
WO2017040606A1 (fr) 2015-08-31 2017-03-09 Proteostasis Therapeutics, Inc. Dérivés d'isoxazole destinés à être utilisés dans le traitement de maladies et de troubles pulmonaires
WO2017062581A1 (fr) 2015-10-06 2017-04-13 Proteostasis Therapeutics, Inc. Composés, compositions et méthodes permettant de moduler le cftr
AU2016379388A1 (en) 2015-12-22 2018-07-12 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
US10662207B2 (en) 2016-04-07 2020-05-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
WO2017196843A1 (fr) 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Procédés d'identification de modulateurs du cftr
US10899751B2 (en) 2016-06-21 2021-01-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
US20190256474A1 (en) 2016-10-26 2019-08-22 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
EP3532467A1 (fr) 2016-10-26 2019-09-04 Proteostasis Therapeutics, Inc. Composés de pyridazine, compositions et méthodes permettant de moduler cftr
WO2018081378A1 (fr) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Composés, compositions et méthodes permettant de moduler cftr
US20200055844A1 (en) 2017-04-28 2020-02-20 Proteostasis Therapeutics, Inc. 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
WO2019133854A1 (fr) 2017-12-29 2019-07-04 Proteostasis Therapeutics, Inc. Procédés de quantification de l'expression de la protéine cftr

Also Published As

Publication number Publication date
CA3000483C (fr) 2024-02-13
CN108430994A (zh) 2018-08-21
NZ741093A (en) 2022-12-23
JP2018537413A (ja) 2018-12-20
US20200385365A1 (en) 2020-12-10
SG11201802798WA (en) 2018-05-30
BR112018007021A2 (pt) 2018-10-16
AU2016336437A1 (en) 2018-04-19
AU2020233776A1 (en) 2020-10-15
BR112018007021B1 (pt) 2024-01-09
EP3359536B1 (fr) 2021-08-04
RU2018116569A (ru) 2019-11-07
IL258486A (en) 2018-05-31
US10550106B2 (en) 2020-02-04
KR20180093882A (ko) 2018-08-22
CA3000483A1 (fr) 2017-04-13
RU2018116569A3 (fr) 2020-02-21
SA518391268B1 (ar) 2021-06-08
AU2016336437B2 (en) 2020-06-18
RU2752567C2 (ru) 2021-07-29
KR20250136942A (ko) 2025-09-16
MX2018004290A (es) 2018-08-09
US20180291006A1 (en) 2018-10-11
MX382725B (es) 2025-03-13
CN108430994B (zh) 2022-04-12
EP3359536A1 (fr) 2018-08-15
HK1258811A1 (en) 2019-11-22
WO2017062581A1 (fr) 2017-04-13
IL258486B (en) 2022-03-01
JP6929276B2 (ja) 2021-09-01
US11136313B2 (en) 2021-10-05
US20220227739A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
IL258486B (en) Compounds, compositions, and methods for modulating cftr
IL286669A (en) Compounds and methods for modulating tmprss6 expression
IL277624A (en) Preparations for modulation of C9ORF72 expression
MA45188A (fr) Oligonucléotides, compositions et méthodes associées
IL251737B (en) Contiguity preserving transposition
EP3183346C0 (fr) Modulateurs de canaux
IL252554A0 (en) A history of mutated 2-anilinopyrimidines as egfr modulators
MA53943A (fr) Modulateurs de ror-gamma
ME03419B (fr) Composés dihydroisoquinolinone substitués
EP3324902C0 (fr) Bouchon lacrymal revêtu
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
GB201410693D0 (en) Splicing modulation
DK3294713T5 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
EP3484524A4 (fr) Composés et procédés de modulation de smn2
LT3536324T (lt) 4-okso-3,4-dihidro-1,2,3-benzotriazinai, kaip gpr139 moduliatoriai
EP3552017A4 (fr) Composés, compositions et méthodes
EP3334783A4 (fr) Réseaux polymères interpénétrants
IL254783A0 (en) Anthelmintic combinations and methods of use thereof
GB201708935D0 (en) Fibre spreading
EP3349703A4 (fr) Applicateur de timbre de tympanoplastie
EP3464236A4 (fr) Composés et méthodes de régénération hématopoïétique
EP3349748A4 (fr) Composition et méthodes correspondantes
EP3302500A4 (fr) Compositions et méthodes de modulation de miarn oncogénique
BR112018002225A2 (pt) dispositivo de dispersão modulado azimutalmente
FI20145460A7 (fi) Sähköisen häiriön rajoittaminen